Insight

Apr 12, 2024, 17:36

Mark Yarchoan: Multicenter P1/2 trial of a personalized neoantigen vaccine + anti-PD1 in 2L HCC presented at AACR24

Mark Yarchoan, Associate Professor at Johns Hopkins Hospital, shared on X:

“Multicenter P1/2 trial of a personalized neoantigen vaccine + anti-PD1 (pembrolizumab) in 2L HCC presented at AACR24 and published in Nature Medicine.

ORR 31%, increased historical control of pembrolizumab monotherapy (~17%)
Details below.

36 patients in US (Mount Sinai NYC, Johns Hopkins Kimmel Cancer Center) and The University of Auckland.

Patients enrolled on 1L TKI treatments (sora or lenva),
DNA vaccine with pIL12 adj targeted up to 40 neos.

ORR 30.6% (11 of 36 patients), 8.3% complete responses

Superiority versus the prespecified historical control (pembrolizumab monotherapy ORR ~17% in HCC),
Randomized trials needed to confirm.

New or increased neoantigen-specific T cell responses detected in 19/22 patients in peripheral blood
Better clinical outcomes for patients with 1) increased neos included in vaccine, and 2) increased strength of neoantigen-specific response.

Significant T cell clonal expansion in 14/14 (100%) patients in peripheral blood and tumor
3 expanded TCR clones were cloned and demonstrated specificity for vaccine-encoded antigens

Expanded TCRs corresponded to highly activated CD8+ and to a lesser degree CD4 effector T cells.

Builds on recent success with melanoma and panc vax in micromet setting; efficacy may extend into advanced disease,
HCC an ideal tumor because T cell priming is impaired in liver (and overcome by vax) – maybe also explain anti-CTLA4 efficacy in HCC.

Congratulations to all authors, Ed Gane, Tom Marron, Daniel Shu,Elana Fertig, Elizabeth Jaffee, Luciane Kagohara, Geneos Therapeutics, and thank you Niranjan Sardesai for the opportunity to join this study even when I was a very junior faculty.”

Proceed to the article.
Source: Mark Yarchoan/X

AACR24 cancer Daniel Shu Ed Gane Elana Fertig Elizabeth Jaffee Geneos Therapeutics HCC hepatocellular carcinoma Johns Hopkins Hospital Johns Hopkins Kimmel Cancer Center Luciane Kagohara Mark Yarchoan Mount Sinai Nature Medicine neoantigen vaccine + anti-PD1 Niranjan Sardesai OncoDaily Oncology Tom Marron University of Auckland

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Special Coverage